000 | 01989 a2200565 4500 | ||
---|---|---|---|
005 | 20250515005858.0 | ||
264 | 0 | _c20060503 | |
008 | 200605s 0 0 fre d | ||
022 | _a0399-077X | ||
024 | 7 |
_a10.1016/j.medmal.2005.10.004 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aToubiana, J | |
245 | 0 | 0 |
_a[Cervical spondylodiscitis: one pathogen may hide another]. _h[electronic resource] |
260 |
_bMedecine et maladies infectieuses _cJan 2006 |
||
300 |
_a55-7 p. _bdigital |
||
500 | _aPublication Type: Case Reports; Journal Article | ||
650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
650 | 0 | 4 |
_aAntitubercular Agents _xadministration & dosage |
650 | 0 | 4 |
_aAza Compounds _xtherapeutic use |
650 | 0 | 4 |
_aCervical Vertebrae _xdiagnostic imaging |
650 | 0 | 4 |
_aCholecystitis _xcomplications |
650 | 0 | 4 |
_aDiscitis _xdrug therapy |
650 | 0 | 4 | _aDisease Progression |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 |
_aEscherichia coli _xisolation & purification |
650 | 0 | 4 |
_aEscherichia coli Infections _xdiagnosis |
650 | 0 | 4 |
_aEthambutol _xadministration & dosage |
650 | 0 | 4 | _aFluoroquinolones |
650 | 0 | 4 | _aFrance |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aImmobilization |
650 | 0 | 4 |
_aIsoniazid _xadministration & dosage |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMorocco _xethnology |
650 | 0 | 4 | _aMoxifloxacin |
650 | 0 | 4 |
_aMycobacterium tuberculosis _xisolation & purification |
650 | 0 | 4 |
_aPyrazinamide _xadministration & dosage |
650 | 0 | 4 |
_aQuinolines _xtherapeutic use |
650 | 0 | 4 | _aRadiography |
650 | 0 | 4 |
_aRifampin _xadministration & dosage |
650 | 0 | 4 |
_aTuberculosis, Spinal _xdrug therapy |
700 | 1 | _aSalomon, J | |
700 | 1 | _aAder, F | |
700 | 1 | _aPerronne, C | |
700 | 1 | _aCarlier, R | |
700 | 1 | _aBernard, L | |
773 | 0 |
_tMedecine et maladies infectieuses _gvol. 36 _gno. 1 _gp. 55-7 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.medmal.2005.10.004 _zAvailable from publisher's website |
999 |
_c15932884 _d15932884 |